Literature DB >> 9178085

NMR study of the peptide present in the principal neutralizing determinant (PND) of HIV-1 envelope glycoprotein gp120.

A V Sarma1, T V Raju, A C Kunwar.   

Abstract

The peptide sequence Gly-Pro-Gly-Arg-Ala-Phe (GPGRAF) is present in many principal neutralizing determinants (PND) of the human immunodeficiency virus type-1 (HIV-1). It has been shown that peptides from the PND sequence contain a significant beta turn in the conserved Gly-Pro-Gly-Arg sequence. In order to find out whether or not the smaller subunits also contain this turn, we have studied the NMR of a hexapeptide [GPGPRAF, peptide (I)], a heptapeptide Gly-Pro-Gly-Arg-Ala-Phe-Cys [GPGRAFC, peptide (II)] and a dodecapeptide [GPGRAFGPGRAF, peptide (III)], retaining the side chain protecting groups. Although the majority of conformations for these peptides are disordered, there is a considerable propensity of structures with beta turn in the GPGR sequence. While peptide (I) and peptide (III) seem to have both type I and type II beta turn conformations, peptide (II) shows a propensity of only type II beta turn. The nascent structures obtained in these peptides may get stabilized as the receptor binding conformation in the presence of the receptors, thus playing a significant role in vaccine development against HIV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178085     DOI: 10.1016/s0165-022x(97)01205-0

Source DB:  PubMed          Journal:  J Biochem Biophys Methods        ISSN: 0165-022X


  2 in total

1.  Probing hydrogen bonds in the antibody-bound HIV-1 gp120 V3 loop by solid state NMR REDOR measurements.

Authors:  J J Balbach; J Yang; D P Weliky; P J Steinbach; V Tugarinov; J Anglister; R Tycko
Journal:  J Biomol NMR       Date:  2000-04       Impact factor: 2.835

2.  Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Susan Zolla-Pazner; Ian A Wilson
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.